Brief: Ventyx Biosciences Announces Initiation Of Dosing In A Phase 1 Trial Of Vtx3232, A Novel Cns-Penetrant Nlrp3 Inhibitor
14/06/2023 12:01
June 14 (Reuters) - Ventyx Biosciences Inc VTYX.O :
* VENTYX BIOSCIENCES ANNOUNCES INITIATION OF DOSING IN A
PHASE 1
TRIAL OF VTX3232, A NOVEL CNS-PENETRANT NLRP3 INHIBITOR
Source text for Eikon: ID:nGNX3QBQnJ
Further company coverage: VTYX.O
Recent news on Ventyx Biosciences
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Healthcare dealmakers head to San Francisco hoping for megamergers in 2026 (updated)
Healthcare dealmakers head to San Francisco hoping for megamergers in 2026
Deals of the day-Mergers and acquisitions